Immunoreactivity of Lewis blood group and mucin peptide core antigens: correlations with grade of dysplasia and malignant transformation in the colorectal adenoma-carcinoma sequence.
Previous studies on the immunoreactivity of various mucin peptide and carbohydrate antigens in neoplastic colorectal tissues led to at least in part contradictory results. Therefore, we investigated a series of 42 adenomas and 44 carcinomas applying monoclonal antibodies (mabs) directed against Lewis blood group antigens (sialyl-Le(a), Le(x), sialyl-Le(x), Le(y)) as well as mucin peptide cores (MUC1, MUC2 and MUC5AC) by immunohistochemistry. A statistically significant positive correlation between the development of high-grade dysplasia in colorectal adenomas and the immunoreactivity of Le(y) and MUC1 epitopes was observed, whereas MUC2 exhibited a significant negative correlation. The reactivity of the other epitopes did not show an association with the progression of malignant transformation. Colorectal carcinomas were subdivided according to their histopathological subtype. The immunohistochemical staining resulted in a significantly stronger MUC2 reactivity of mucinous vs. tubular adenocarcinomas. Immunoreactivity of the MUC1-specific mab, which does not react with the fully glycosylated peptide core, showed a statistically non-significant inverse tendency, whereas all carbohydrate antigens displayed a strong expression in both tumor subtypes. Furthermore, correlations between mucin peptide and carbohydrate epitope labelling were evaluated. Progression of the adenoma-carcinoma sequence was accompanied by an increase of Le(y) as well as MUC1 antigen and an increase of all Lewis antigens compared to MUC2 immunoreactivity. On the other hand, mucinous carcinomas exhibited an inverse pattern. In conclusion, these results demonstrate that Le(y) and MUC1 immunoreactivity correlate with malignant transformation in the colorectum, whereas MUC2 represents a marker for low-grade dysplasia and the subtype of mucinous carcinomas.
Baldus
S E
SE
Institute of Pathology, University of Cologne, Germany. s-e.baldus@unin-koeln.de
Hanisch
F G
FG
Pütz
C
C
Flucke
U
U
Mönig
S P
SP
Schneider
P M
PM
Thiele
J
J
Hölscher
A H
AH
Dienes
H P
HP
D000236:Adenoma / Q000276:immunology* / Q000473:pathology*; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm / Q000276:immunology; D002241:Carbohydrates / Q000276:immunology; D002277:Carcinoma / Q000276:immunology* / Q000473:pathology*; D002471:Cell Transformation, Neoplastic / Q000276:immunology* / Q000473:pathology*; D015179:Colorectal Neoplasms / Q000276:immunology* / Q000473:pathology*; D018450:Disease Progression; D006031:Glycosylation; D006801:Humans; D007150:Immunohistochemistry; D007983:Lewis Blood Group Antigens / Q000276:immunology*; D018396:Mucin-1 / Q000276:immunology*; D055262:Mucin-2; D009077:Mucins / Q000276:immunology*; D009844:Oligosaccharides / Q000096:biosynthesis / Q000235:genetics; D016612:Paraffin Embedding; D010455:Peptides / Q000276:immunology; D016707:Tissue Fixation
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D002241:Carbohydrates; D007983:Lewis Blood Group Antigens; C524625:MUC2 protein, human; D018396:Mucin-1; D055262:Mucin-2; D009077:Mucins; D009844:Oligosaccharides; D010455:Peptides